SAG
CORT icon

SageView Advisory Group’s Corcept Therapeutics CORT Stock Holding History

SageView Advisory Group’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-540
Closed -$18.8K – 980
2025
Q4 		$18.8K Buy
+540
New +$42.4K ﹤0.01% 1481

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

SageView Advisory Group's CORT Position: Q1 2026 in Review

SageView Advisory Group sold out of Corcept Therapeutics (CORT) in Q1 2026, closing a stake of 540 shares — an estimated $18.8K sold.

SageView Advisory Group first reported a position in CORT in Q4 2025 and held it in 1 quarter. The position peaked at $18.8K in Q4 2025. 352 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

  • SageView Advisory Group reported no remaining Corcept Therapeutics position as of Q1 2026 after selling out during the quarter.
  • SageView Advisory Group sold 540 Corcept Therapeutics shares in Q1 2026, an estimated $18.8K.
  • SageView Advisory Group first reported a position in Corcept Therapeutics in Q4 2025 and held it in 1 quarter.
  • SageView Advisory Group's Corcept Therapeutics position peaked at $18.8K in Q4 2025.
  • 352 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on SageView Advisory Group's 13F filing for Q1 2026, filed 10 Aug 2026.